On April 9, 2021 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported plans to host a conference call and webcast on Friday, April 16, 2021 at 8:00 a.m. ET to discuss the selection of the NaPi2b biomarker cutoff and the commercial diagnostic development path for the ongoing UPLIFT registration strategy in platinum-resistant ovarian cancer (Press release, Mersana Therapeutics, APR 9, 2021, https://ir.mersana.com/news-releases/news-release-details/mersana-therapeutics-host-conference-call-and-webcast-discuss [SID1234577791]). The presentation will review the Company’s plan to deliver a robust, predictive and reproducible commercial diagnostic assay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4598737. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.